Shareholder rights law firm Johnson & Weaver, LLP is investigating
potential violations of the federal securities laws by Dr. Reddy's
Laboratories Ltd. (NYSE: RDY) and certain of its officers. Dr.
Reddy’s operates as an integrated pharmaceutical company worldwide.
On November 6, 2015, Dr. Reddy's reported that the Company received a
"warning letter" from U.S. regulators over inadequate quality controls
at three manufacturing plants producing drugs for cancer and other
diseases.
Dr. Reddy's said the FDA warning meant it would not receive U.S.
approvals for drugs made at the plants until it fixed the problems. The
manufacturing plants account for more than 10 percent to 12 percent of
Dr. Reddy's sales.
If you have information that could assist in this investigation, or
if you are a Dr. Reddy's shareholder and are interested in learning more
about the investigation or your legal rights and remedies, please
contact Jim Baker (jimb@johnsonandweaver.com) by
email or by phone at 619-814-4471. If emailing, please include a phone
number where you can be reached.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law
firm with offices in California, New York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more information
about the firm and its attorneys, please visit http://www.johnsonandweaver.com.
Attorney advertising. Past results do not guarantee future outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151106005865/en/
Copyright Business Wire 2015